PRNewsWire
27 Apr 2026, 11:45 UTC · 29w ago
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Verdict
Headline takes no side. We score JAZZ +0.80 — strongly bullish.
- Expected · JAZZ
+0.80strongly bullish
−1 bearish0bullish +1More positive than 88% of ticker scores this week





